Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 200-346-4 | CAS number: 57-68-1
Endpoint summary
Administrative data
Description of key information
No data is available for skin and respiratory sensitisation of Sulfadimidine. No reason of concern regarding skin sensatisation comes from QSAR analysis. No evidence of common skin or eye sensitisation from patients treated with Sulfamidimidine.
Key value for chemical safety assessment
Skin sensitisation
Endpoint conclusion
- Endpoint conclusion:
- no study available
- Additional information:
No data is available for skin sensitisation of Sulfadimidine. No reason of concern regarding skin sensatisation comes from QSAR analysis.
Sulfadimidine is a transported isolated intermediate, it is used under strictly controlled conditions so the exposure for worker to Sulfadimidine is minimized and there is no exposure for general population. Moreover, as reported inIARC Monographs, Vol.79, 2001, p.344 Sulfamethazine (synonym of Sulfadimidine) is use to treat a variety of bacterial diseases in human and in other species and it is given generally as sodium salt orally or parenterally. There is no evidence of common skin or respiratory sensitisation in patients treated with Sulfamidimidine (no specific case report in HSDB Report of Sulmethazine-synonym of Sulfadimidine).
Respiratory sensitisation
Endpoint conclusion
- Endpoint conclusion:
- no study available
- Additional information:
No data is available for respiratory sensitisation of Sulfadimidine.
Sulfadimidine is a transported isolated intermediate, it is used under strictly controlled conditions so the exposure for worker to Sulfadimidine is minimized and there is no exposure for general population. Moreover, as reported in IARC Monographs, Vol.79, 2001, p.344 Sulfamethazine (synonym of Sulfadimidine) is use to treat a variety of bacterial diseases in human and in other species and it is given generally as sodium salt orally or parenterally. There is no evidence of common skin or respiratory sensitisation in patients treated with Sulfamidimidine (no specific case report in HSDB Report of Sulmethazine-synonym of Sulfadimidine).
Justification for classification or non-classification
No data is available for skin/respiratory sensitisation of Sulfadimidine. No reason of concern regarding skin sensatisation comes from QSAR analysis. No evidence of common skin or eye sensitisation from patients treated with Sulfamidine.
Sulfadimidine is a transported isolated intermediate, it is used under strictly controlled conditions so the exposure for worker to Sulfadimidine is minimized and there is no exposure for general population.
No classification is proposed for skin/respiratory sensatisation of Sulfametidine according to the CLP regulation (EC n. 1272/2008).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
